First, our experimental models primarily reflect features of acral melanoma and the identified high-risk TEAD3 + subgroup; thus, the generalizability to other melanoma subtypes (e.g., BRAF or NRAS mutant, or triple wild-type tumors) requires further validation. This evidence concerns the gene NRAS and acral lentiginous melanoma.